PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15990245-0	2005	Tamoxifen may increase insulin requirement in breast cancer patients with type 1 diabetes mellitus through its agonistic activity on splenic endothelial cells and inhibitory effect on pancreatic beta cells.	Tamoxifen	0-9	insulin	Homo sapiens	23-30	
1380889-0	1992	Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.	Tamoxifen	13-22	insulin	Homo sapiens	43-50	
15387438-4	2004	In a human serum matrix the MELN system was able to detect the transcriptional activity of estradiol, growth factors (epidermal growth factor (EGF), insulin at insulin-like growth factor 1 (IGF-1)-like concentrations), xeno-estrogens (diethylstilbestrol, phytoestrogens) and tamoxifen in a dose-dependent manner.	Tamoxifen	275-284	insulin	Homo sapiens	149-156	
12016549-5	2002	In other instances, corticosteroids, tamoxifen, and estrogens may precipitate NASH in predisposed persons by exacerbating insulin resistance, central obesity, diabetes, and hypertriglyceridemia, and methotrexate may worsen hepatic fibrosis in NASH.	Tamoxifen	37-46	insulin	Homo sapiens	122-129	
1380889-4	1992	These findings suggest that tamoxifen exerts its influence on plasma IGF-I and IGFBP-I by mechanisms other than those known to regulate the plasma levels of these peptides, primarily growth hormone and insulin, respectively.	Tamoxifen	28-37	insulin	Homo sapiens	202-209	
2285590-2	1990	In addition to its anti-estrogenic action requiring estrogen receptor (ER) and leading to growth arrest, we have previously shown that the anti-hormone tamoxifen (Tam) is able to block EGF, insulin and IGF-I mitogenic activities in total absence of estrogens (BBRC, 146,1502,1987).	Tamoxifen	152-161	insulin	Homo sapiens	190-197	
2285590-2	1990	In addition to its anti-estrogenic action requiring estrogen receptor (ER) and leading to growth arrest, we have previously shown that the anti-hormone tamoxifen (Tam) is able to block EGF, insulin and IGF-I mitogenic activities in total absence of estrogens (BBRC, 146,1502,1987).	Tamoxifen	163-166	insulin	Homo sapiens	190-197	
7004631-1	1981	The effect of the antiestrogens tamoxifen and nafoxidine on the growth of the human breast cancer cell line MCF-7 is modified by both serum and insulin.	Tamoxifen	32-41	insulin	Homo sapiens	144-151	
35180212-4	2022	Upon tamoxifen induction of transgene expression, NDM mice rapidly developed severe diabetes followed by an unexpected loss of insulin content, decreased proinsulin processing and increased proinsulin at 2-weeks of diabetes.	Tamoxifen	5-14	insulin	Homo sapiens	127-134	
3542712-4	1986	Insulin in the presence of tamoxifen, also enhanced rp mRNA levels suggesting increased levels are a reflection of cell proliferation as opposed to specific hormonal regulation.	Tamoxifen	27-36	insulin	Homo sapiens	0-7	
7004631-5	1981	Cells growing in media containing insulin are less sensitive to inhibition by either tamoxifen or nafoxidine than are cells growing in its absence.	Tamoxifen	85-94	insulin	Homo sapiens	34-41	
27837347-4	2017	The mechanism of TAM resistance in the ER+ breast cancer cell line MCF-7 was investigated, and the results showed that the stimulating effect of insulin on susceptibility of MCF-7 to TAM was mediated by ER-alpha36 and that the expression level of ER-alpha36 in TAM-resistant MCF-7 cells was also significantly increased.	Tamoxifen	17-20	insulin	Homo sapiens	145-152	
27837347-4	2017	The mechanism of TAM resistance in the ER+ breast cancer cell line MCF-7 was investigated, and the results showed that the stimulating effect of insulin on susceptibility of MCF-7 to TAM was mediated by ER-alpha36 and that the expression level of ER-alpha36 in TAM-resistant MCF-7 cells was also significantly increased.	Tamoxifen	183-186	insulin	Homo sapiens	145-152	
26548081-4	2015	In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model.	Tamoxifen	284-293	insulin	Homo sapiens	159-166	
17163263-4	2006	We report on a patient with tamoxifen-induced acute pancreatitis and hypertriglyceridaemia who was successfully treated with insulin infusion and long-term gemfibrozil.	Tamoxifen	28-37	insulin	Homo sapiens	125-132	
16322340-5	2005	In the presence of insulin, growth of LTED cells was refractory to TAM but inhibited by ICI and E2.	Tamoxifen	67-70	insulin	Homo sapiens	19-26	
22669764-3	2012	We show that phosphorylation of a neighboring hinge domain site, Ser294, analyzed by multiple reaction monitoring mass spectrometry of ERalpha immunoprecipitates from human breast cancer cells is robustly phosphorylated exclusively by ligand (estradiol and tamoxifen) activation of ERalpha and not by growth factor stimulation (EGF, insulin, heregulin-beta).	Tamoxifen	257-266	insulin	Homo sapiens	333-340	
21908557-7	2011	Finally, an insulin/IGF-I gene expression signature predicted recurrence-free survival in patients with ER(+) breast cancer treated with the antiestrogen tamoxifen.	Tamoxifen	154-163	insulin	Homo sapiens	12-19	
19010927-0	2008	Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.	Tamoxifen	35-44	insulin	Homo sapiens	48-55	
16631425-8	2006	The suppression was reversed if cells were incubated with 10(-11) to 10(-7) M tamoxifen or ICI 182,780 combined with 10(-11) or 10(-9) M estradiol followed by incubation with 5 microg/ml insulin, indicating an estrogen receptor-mediated process.	Tamoxifen	78-87	insulin	Homo sapiens	187-194